eClinical Technology and Industy News

Akamis Bio, Parker Institute for Cancer Immunotherapy, and Cancer Research Institute Announce Expanded Partnership to Advance Novel Treatments for Pancreatic Cancer

Akamis Bio’s clinical-stage NG-350A tumor gene therapy to be included as a novel combination therapeutic agent in a new cohort of the REVOLUTION platform study

New cohort will assess the ability of NG-350A in combination with ipilimumab and standard of care chemotherapy to drive a CD40 agonist-mediated antitumor immune response in metastatic pancreatic cancer

Excerpt from the Press Release:

CAMBRIDGE, Mass. & OXFORD, England–(BUSINESS WIRE)–Akamis Bio, a clinical-stage oncology company leveraging its Tumor-Specific Immuno-Gene Therapy (T-SIGn®) platform to positively impact the lives of people living with cancer, today announced an expansion of its ongoing partnership with the Parker Institute for Cancer Immunotherapy (PICI) to include a clinical collaboration with the Cancer Research Institute (CRI) that will focus on advancing novel treatments for pancreatic cancer.

As part of the Akamis Bio, PICI, and CRI partnership, NG-350A, an immuno-stimulatory tumor gene therapy driving intratumoral expression of a CD40 agonist monoclonal antibody, will be evaluated in combination with standard-of-care chemotherapy and the CTLA-4 inhibitor ipilimumab (YERVOY®). The NG-350A combination therapy will be part of cohort C in REVOLUTION, a platform clinical study investigating novel therapeutic combinations for the treatment of previously untreated metastatic pancreatic cancer.

NG-350A is a clinical-stage, intravenously delivered T-SIGn® therapeutic whose mechanism of action is based on CD40-mediated activation of antigen-presenting cells (APCs) resident in solid tumors and their draining lymph nodes. Once activated, APCs recruit T cells into the vicinity of the tumor to deliver a potent anti-tumor immune response. NG-350A has the potential for use as both a monotherapy and in combination with other immuno-oncology agents.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary EDC Platforms

Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?